Clinical Trials Search Results
Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.
Condition: HIV InfectionNCT ID: NCT01275443
Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects
Condition: HIV PositiveNCT ID: NCT02404233
Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age
Condition: HIV InfectionsNCT ID: NCT01975012
Pre-Exposure Prophylaxis Using TMC278LA
Condition: HIV InfectionsNCT ID: NCT01049932
TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
Condition: HIV Infections; HIV-1NCT ID: NCT00543725
A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
Condition: HIV; HIV Infections; PregnancyNCT ID: NCT00855335
A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.
Condition: HIVNCT ID: NCT01736761
Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
Condition: HIVNCT ID: NCT02104700
Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.
Condition: HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With MenNCT ID: NCT01715636
TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
Condition: HIV Infections; HIV-1; Human Immunodeficiency Virus Type 1NCT ID: NCT00540449
Clinical Trial News
- Wednesday, April 5, 2017
- NIDA Announces Recipients of 2017 Avant-Garde Awards for HIV/AIDS Research
- Tuesday, March 14, 2017
- Dual Antibody Treatment Suppresses HIV-Like Virus in Monkeys
- Monday, March 13, 2017
- Monkeys Suppress HIV-Like Virus for Extended Period After Dual-Antibody Treatment
- Call 1-800-448-0440
(1 p.m. to 4 p.m. ET)
- Send us an email